Log in
NASDAQ:AXNX

Axonics Modulation Technologies Stock Forecast, Price & News

$44.26
+1.13 (+2.62 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$43.14
Now: $44.26
$45.08
50-Day Range
$42.19
MA: $46.80
$51.50
52-Week Range
$15.25
Now: $44.26
$52.10
Volume343,675 shs
Average Volume625,096 shs
Market Capitalization$1.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.01
Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.92 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXNX
CUSIPN/A
CIKN/A
Phone949-396-6322
Employees302

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.82 million
Book Value$7.38 per share

Profitability

Net Income$-79,930,000.00

Miscellaneous

Market Cap$1.76 billion
Next Earnings Date3/3/2021 (Estimated)
OptionableNot Optionable
$44.26
+1.13 (+2.62 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Axonics Modulation Technologies (NASDAQ:AXNX) Frequently Asked Questions

How has Axonics Modulation Technologies' stock been impacted by COVID-19 (Coronavirus)?

Axonics Modulation Technologies' stock was trading at $30.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXNX shares have increased by 46.5% and is now trading at $44.26.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Axonics Modulation Technologies?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Axonics Modulation Technologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Axonics Modulation Technologies?

Wall Street analysts have given Axonics Modulation Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axonics Modulation Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Axonics Modulation Technologies' next earnings date?

Axonics Modulation Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Axonics Modulation Technologies
.

How were Axonics Modulation Technologies' earnings last quarter?

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.28. The business earned $35.24 million during the quarter, compared to analyst estimates of $22.95 million. Axonics Modulation Technologies had a negative net margin of 76.62% and a negative return on equity of 28.05%. The company's quarterly revenue was up 2592.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.89) earnings per share.
View Axonics Modulation Technologies' earnings history
.

What price target have analysts set for AXNX?

8 Wall Street analysts have issued 12-month target prices for Axonics Modulation Technologies' shares. Their forecasts range from $48.00 to $77.00. On average, they expect Axonics Modulation Technologies' share price to reach $58.89 in the next twelve months. This suggests a possible upside of 33.1% from the stock's current price.
View analysts' price targets for Axonics Modulation Technologies
.

Who are some of Axonics Modulation Technologies' key competitors?

What other stocks do shareholders of Axonics Modulation Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

Who are Axonics Modulation Technologies' key executives?

Axonics Modulation Technologies' management team includes the following people:
  • Mr. Raymond W. Cohen, CEO & Director (Age 61, Pay $871.2k)
  • Mr. Danny L. Dearen, Pres & CFO (Age 57, Pay $636.2k)
  • Mr. Rinda K. Sama, Chief Operating Officer (Age 41, Pay $536.2k)
  • Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 47)
  • Mr. Neil Bhalodkar, VP of Investor Relations
  • Mr. Aaron Pettit, Gen. Counsel & Chief Compliance Officer
  • Mr. John Woock Ph.D., Chief Marketing Officer (Age 37)
  • Mr. Michael V. Williamson, Sr. VP, Gen. & IP Counsel (Age 49)
  • Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 57)
  • Mr. Prabodh Mathur, Chief Product Devel. Officer (Age 60)

When did Axonics Modulation Technologies IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics Modulation Technologies' stock symbol?

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics Modulation Technologies' major shareholders?

Axonics Modulation Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.41%), AXA S.A. (3.37%), Lord Abbett & CO. LLC (3.19%), Polar Capital LLP (2.57%), Polar Capital LLP (2.57%) and State Street Corp (1.96%). Company insiders that own Axonics Modulation Technologies stock include Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen and Rinda Sama.
View institutional ownership trends for Axonics Modulation Technologies
.

Which institutional investors are selling Axonics Modulation Technologies stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, AXA S.A., Thrivent Financial for Lutherans, Peregrine Capital Management LLC, Iron Triangle Partners LP, First Trust Advisors LP, Polar Capital LLP, and Polar Capital LLP. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raymond W Cohen, and Rinda Sama.
View insider buying and selling activity for Axonics Modulation Technologies
.

Which institutional investors are buying Axonics Modulation Technologies stock?

AXNX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Columbus Circle Investors, BlackRock Inc., Federated Hermes Inc., WINTON GROUP Ltd, Castleark Management LLC, Advisory Research Inc., and State Street Corp. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Nancy Lynn Md Snyderman, and Raymond W Cohen.
View insider buying and selling activity for Axonics Modulation Technologies
.

How do I buy shares of Axonics Modulation Technologies?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axonics Modulation Technologies' stock price today?

One share of AXNX stock can currently be purchased for approximately $44.26.

How big of a company is Axonics Modulation Technologies?

Axonics Modulation Technologies has a market capitalization of $1.76 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Axonics Modulation Technologies employs 302 workers across the globe.

What is Axonics Modulation Technologies' official website?

The official website for Axonics Modulation Technologies is www.axonics.com.

How can I contact Axonics Modulation Technologies?

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.